A new insulin-enhancing agent: [N,N'-bis(4-hydroxysalicylidene)-o-phenylene-diamine]oxovanadium(IV) and its permeability and cytotoxicity.
A new insulin-enhancing agent: [N,N'-bis(4-hydroxysalicylidene)-o-phenylene-diamine] oxovanadium(IV) (BPOV) was synthesized and characterized by X-ray crystallography. BPOV was administered intragastrically to STZ-diabetic rats for 4 weeks. The results showed that BPOV could significantly decrease the blood glucose level and ameliorated impaired glucose tolerance in STZ-diabetic rats. BPOV has been further tested on insulin, glycogen and serum lipid studies. The results suggested BPOV has glucose-lowering activity in diabetic rats, as well as improved the disorder of lipid metabolism in diabetes. BPOV had permeability above 10(-5) cm s(-1). It was suggested good lipophilic properties. The cytotoxicity of BPOV on Caco-2 cells was measured by MTT assay which suggested BPOV have higher effect on impairment of cellular associated with lower level capacity of cellular accumulation.